Randomised placebo-controlled trial of combination ACE inhibitor and betablocker therapy to prevent cardiomyopathy in children with Duchenne muscular dystrophy? (DMD Heart Protection Study): a protocol study

被引:18
作者
Bourke, John P. [1 ]
Watson, Gillian [2 ]
Muntoni, Francesco [3 ,4 ,5 ]
Spinty, Stefan [6 ]
Roper, Helen [7 ]
Guglieri, Michela [8 ]
Speed, Chris [2 ]
McColl, Elaine [2 ]
Chikermane, Ashish [9 ]
Jayawant, Sandeep [10 ]
Adwani, Satish [11 ]
Willis, Tracey [12 ]
Wilkinson, Jennifer [2 ]
Bryant, Andrew [13 ]
Chadwick, Thomas [13 ]
Wood, Ruth [2 ]
Bushby, Kate [8 ]
机构
[1] NUTH NHS Hosp Fdn Trust, Freeman Hosp, Dept Cardiol, Newcastle Upon Tyne, Tyne & Wear, England
[2] Newcastle Univ, Clin Trials Unit, Newcastle Upon Tyne, Tyne & Wear, England
[3] Dubowitz Neuromuscular Ctr, Dev Neurosc, London, England
[4] Inst Child Hlth, London, England
[5] Great Ormond St Hosp Children NHS Fdn Trust, London, England
[6] Alder Hey Childrens NHS Fdn Trust, Dept Paediat Neurol, Liverpool, Merseyside, England
[7] Heart England NHS Fdn Trust, Dept Paediat, Birmingham, W Midlands, England
[8] Newcastle Univ, John Walton Muscular Dystrophy Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England
[9] Birmingham Childrens Hosp NHS Fdn Trust, Dept Cardiol, Birmingham, W Midlands, England
[10] Oxford Univ Hosp NHS Fdn Trust, Dept Paediat Neurol, Oxford, England
[11] Oxford Univ Hosp NHS Fdn Trust, Dept Paediat Cardiol, Oxford, England
[12] Robert Jones & Agnes Hunt Hosp, Muscle Team, Oswestry, Shrops, England
[13] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne, Tyne & Wear, England
关键词
VENTRICULAR SYSTOLIC DYSFUNCTION; CONVERTING ENZYME-INHIBITORS; DILATED CARDIOMYOPATHY; ENALAPRIL; SURVIVAL; FAILURE; LIFE; PERINDOPRIL; DEFLAZACORT; PROGRESSION;
D O I
10.1136/bmjopen-2018-022572
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Although cardiologists were 'late-comers' to the multidisciplinary team-contributing to the complex care of patients with Duchenne muscular dystrophy (DMD), they now recognise the importance of systematic cardiac surveillance and timely therapy to prolonged survival in patients with DMD. Empirical deployment of cardioactive medications has already improved outcomes, but the evidence base for clinical decision making is weak. Fundamental questions remain as to whether prophylactic therapy is justified and convincingly superior to prompt deployment of the same therapies once left ventricular (LV) dysfunction is detected. Even if it were, at what age should therapy be introduced and with what specific drugs? Methods and analysis We are conducting a multicentre, parallel group, randomised, placebo-controlled study of combination therapy with an ACE inhibitor (perindopril) and a beta-blocker (bisoprolol) in boys with DMD aged 5-13 years, with normal LV function by echocardiographic criteria at the time of recruitment. Boys are being followed-up for a minimum of 3 years and a maximum of 5 years and undergo repeat assessments of LV function, heart rate and ECG, forced expiratory volume in the 1 s and forced vital capacity, adverse event reporting and quality of life at 6 monthly intervals. The primary outcome is change in LV function between active and placebo-treated participants over the course of the study. Ethics and dissemination The study was approved by 'NRES Committee East Midlands - Derby'. The results will be disseminated through manuscript publications, an international workshop and presentations to scientific meetings and parent forums. Translational aspects The study seeks to establish the evidence for prophylactic heart therapies for children with DMD, define the optimum age for their introduction and identify any safety concerns. Article summary The protocol describes the design of an ongoing multicentre, double-blind, randomised placebo-controlled study to establish the evidence for the use of prophylactic heart therapies in children with DMD, define the optimum age for their introduction and identify any safety concerns.
引用
收藏
页数:9
相关论文
共 50 条
[1]  
Allen HD, 2013, PLOS CURRENTS MUSCUL, V5, P1
[2]  
[Anonymous], PLOS CURR
[3]  
[Anonymous], 1999, LANCET, V353, P138
[4]  
BACKMAN E, 1992, EUR HEART J, V13, P1239
[5]   Oral Corticosteroids and Onset of Cardiomyopathy in Duchenne Muscular Dystrophy [J].
Barber, Brent J. ;
Andrews, Jennifer G. ;
Lu, Zhenqiang ;
West, Nancy A. ;
Meaney, F. John ;
Price, Elinora T. ;
Gray, Ashley ;
Sheehan, Daniel W. ;
Pandya, Shree ;
Yang, Michele ;
Cunniff, Christopher .
JOURNAL OF PEDIATRICS, 2013, 163 (04) :1080-+
[6]   Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade [J].
Biggar, WD ;
Harris, VA ;
Eliasoph, L ;
Alman, B .
NEUROMUSCULAR DISORDERS, 2006, 16 (04) :249-255
[7]   Absence of Cardiac Benefit with Early Combination ACE Inhibitor and Beta Blocker Treatment in mdx Mice [J].
Blain, Alison ;
Greally, Elizabeth ;
Laval, Steven H. ;
Blamire, Andrew M. ;
MacGowan, Guy A. ;
Straub, Volker W. .
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2015, 8 (03) :198-207
[8]   Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction A Network Meta-Analysis [J].
Burnett, Heather ;
Earley, Amy ;
Voors, Adriaan A. ;
Senni, Michele ;
McMurray, John J. V. ;
Deschaseaux, Celine ;
Cope, Shannon .
CIRCULATION-HEART FAILURE, 2017, 10 (01)
[9]   Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care [J].
Bushby, Katharine ;
Finkel, Richard ;
Birnkrant, David J. ;
Case, Laura E. ;
Clemens, Paula R. ;
Cripe, Linda ;
Kaul, Ajay ;
Kinnett, Kathi ;
McDonald, Craig ;
Pandya, Shree ;
Poysky, James ;
Shapiro, Frederic ;
Tomezsko, Jean ;
Constantin, Carolyn .
LANCET NEUROLOGY, 2010, 9 (02) :177-189
[10]   Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy [J].
Cicoira, M ;
Zanolla, L ;
Franceschini, L ;
Rossi, A ;
Golia, G ;
Zeni, P ;
Caruso, B ;
Zardini, P .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (04) :403-407